EDITORIAL SECTION

Articles

Innovative Pricing Models in the EU: Making Medicines Affordable for All

Pricing policies are important determinants in delivering sufficiently cheap medicines in all the member nations of the EU High costs of meeting the required medical care together with arising independent differentiated technological improvements have rendered exhausted pricing structures as uncompetitive tools for fairness New mechanisms of pricing have been introduced

Emerging Therapies in Oncology: Advances beyond Traditional Chemotherapy

Cancer formerly was treated by traditional chemotherapy which is a process that employs the use of powerful drugs to eliminate spreading cancer cells Chemotherapy has been a standard for cancer treatment

Business Transformation Strategies for the Pharmaceutical Industry

The pharmaceutical industry is at a crossroads Drug development timelines remain long regulatory scrutiny keeps intensifying and patients now expect the same seamless digital experiences they get from banking apps or online retailers Against this backdrop pharma business transformation has moved from a nicetohave to a survival requirement

Patient-Centered Approaches In Pharma: From R&D to the Future

The pharmaceutical industry is undergoing a paradigm shift towards patientcentered approaches recognizing the importance of considering patient perspectives throughout the drug development and healthcare delivery process

AI Governance in Pharma: Managing Trust, Transparency, and Regulatory Expectations

Most large pharmaceutical organisations no longer have an AI strategy problem They have an AI accountability problem Models now sit inside pharmacovigilance case intake deviation triage visual inspection trial feasibility medical information and commercial targeting deployed by different functions on different platforms under different assumptions about who signs

EU Pharma Reform 2025 Explained: What Market Access Leaders Must Know for 2026-2029

What if your EU market exclusivity depends on launching your medicine in every member state and proving its realworld value This is no longer hypothetical The historic Pharma Reform agreement of the Council of the EU of March is the first major revision of pharmaceutical legislation in more than years It will have a significant impact on the way businesses will enter the market set their prices...

Techno Trends

Alume Biosciences Secures FDA Breakthrough Therapy Designation for Bevonescein

Alume Biosciences has received Breakthrough Therapy Designation BTD from the US Food and Drug Administration FDA for bevonescein an investigational fluorescent drug being developed to support realtime nerve visualisation during head and neck surgery in adults Bevonescein is an intravenous fluorescent peptidedye conjugate that binds to nerve tissue

Projects

SK pharmteco Plans More Than US$200 Million Investment in Small Molecule and Peptide Manufacturing

SK pharmteco is planning a fiveyear investment of more than US million to expand and modernise its pharmaceutical development and manufacturing operations in the United States The programme will strengthen capabilities for small molecules and peptides while supporting a more

Research Insights

One-month physicochemical stability study of idarubicin prepared in polyolefin-type bags for the treatment of hematological diseases

Idarubicine is a mainstay of the treatment strategy for hematological cancer The literature lacks stability data that comply with current preparation practices and recommendations for conducting stability studies

whitepaper

Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact

For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys